Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.

Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. Cancer Cell. 2014 Jul 14; 26(1):7-9.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.